PegBio Co., Ltd. said its next-generation GLP-1 receptor agonist candidate CR059, developed using circular RNA protein replacement technology and delivered via a lipid nanoparticle system, has completed single-dose administration in a first-in-human trial in subjects with type 2 diabetes and has obtained four-week clinical observations. The company reported that four weeks after a single dose, glycated hemoglobin (HbA1c) and fasting blood glucose continued to improve versus baseline, continuous glucose monitoring showed time in range (4–10 mmol/L) increased, and mean blood glucose decreased. In preclinical studies, PegBio reported that in db/db mice CR059 showed a clear dose-response and superior metabolic intervention effects versus semaglutide under head-to-head conditions. In a spontaneous type 2 diabetes rhesus monkey model, once-monthly subcutaneous dosing (D1 and D32) significantly reduced fasting plasma glucose with effects persisting across the dosing interval, and HbA1c continued improving versus baseline until D88. In healthy rhesus monkeys, a single subcutaneous dose was reported to maintain metabolic effects for several weeks, with approximately 11.8% weight loss at five weeks after one administration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260306-12044046), on March 06, 2026, and is solely responsible for the information contained therein.